Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients

Neuroendocrinology Letters

Volumn 23, Issue 1, 2002, Pages 61-63

  Lissoni, Paolo ^a   Malugani, Fabio ^a   Casu, Marilena ^a   Bukovec, Roberta ^a   Egardi, Remo ^a   Bordin, Veronica ^a   Fumagalli, Elena ^a   Mengo, Susan ^a   Gardani, Gianstefano ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Anti androgens; Bicalutamide; L dopa; Prolactin; Prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CORTICOSTEROID; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUTAMIDE; GONADORELIN DERIVATIVE; LEVODOPA; OPIATE; PROLACTIN;

ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; MALE; METASTASIS; PROGNOSIS; PROLACTIN RELEASE; PROSTATE CANCER; RADIOIMMUNOASSAY;

EID: 0036189155     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Effect of prolactin on the prostate
2. Growth factors and prostatic tumors
3. In vivo characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate
4. A phase II study of bromocriptine in patients with androgen-independent prostate cancer
5. Influence of radical prostatectomy on serum hormone levels
6. Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate
7. Luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue
8. Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate-cancer-and its possible role in prostate cancer-related hyperprolactinemia
9. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate
10. Bicalutamide in the treatment of advanced prostatic carcinoma: A phase II non comparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy
11. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial
12. Endocrine profiles during administration of the new nonsteroidal anti-androgen Casodex in prostate cancer